SCHEMBL128913

SCHEMBL128913

O=C(C=Cc1ccc(O)cc1)c1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 1.00
KMT2A Q03164 6/20 1.00
MAOA P21397 5/20 1.00
MAOB P27338 5/20 1.00
MAPK1 P28482 5/20 1.00
CYP3A4 P08684 5/20 1.00
MEN1 O00255 4/20 1.00
TDP1 Q9NUW8 4/20 1.00
KDM4E B2RXH2 3/20 1.00
HPGD P15428 3/20 1.00
ALOX15 P16050 3/20 1.00
TP53 P04637 2/20 1.00
ALDH1A1 P00352 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
ALOX12 P18054 1/20 1.00
CYP2C19 P33261 4/20 0.80
BCHE P06276 1/20 0.80
NPSR1 Q6W5P4 2/20 0.71
GAA P10253 1/20 0.71
PTGS1 P23219 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3291572 1.00 MAPT (1.00) MAPTKMT2AMAOAMAOBMAPK1
SCHEMBL30383395 1.00 MAPT (1.00) MAPTKMT2AMAOAMAOBMAPK1
SCHEMBL25199026 1.00 MAPT (1.00) MAPTKMT2AMAOAMAOBMAPK1
SCHEMBL30918566 1.00 MAPT (1.00) MAPTKMT2AMAOAMAOBMAPK1
SCHEMBL25195966 0.94 MAOB (0.89) MAPTKMT2AMAOAMAOBMAPK1
SCHEMBL25219836 0.94 MAOB (0.89) MAPTKMT2AMAOAMAOBMAPK1
SCHEMBL25191373 0.94 MAOB (0.89) MAPTKMT2AMAOAMAOBMAPK1
SCHEMBL25233412 0.94 MAOB (0.89) MAPTKMT2AMAOAMAOBMAPK1
Isoliquiritigenin SCHEMBL9448617 0.89 CYP3A4 (0.86) MAPTKMT2AMAOAMAOBMAPK1
Isoliquiritigenin SCHEMBL9448612 0.89 CYP3A4 (0.86) MAPTKMT2AMAOAMAOBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECH INC (US) 2026-04-09 US claimed
US-20230003721-A1 MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2023-01-05 US claimed
US-20220330565-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECHNOLOGY, INC. 2022-10-20 US claimed
WO-2020068665-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2020-04-02 WO claimed
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2019-11-07 US claimed
US-9877946-B2 Method for treating, managing, inhibiting, or preventing obesity Research & Business Foundation Sungkyunkwan University (KR) 2018-01-30 US claimed
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVER SITY (KR) 2017-03-30 US claimed
US-9549908-B2 Composition for inducing differentiation into beige and brown adipocytes and method of inducing the same Research & Business Foundation Sungkyunkwan University, Ltd. (KR) 2017-01-24 US claimed
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2015-12-31 US claimed
US-20090222946-A1 DNA SEQUENCES INVOLVED IN PRENYLFLAVONOID BIOSYNTHESIS IN HOPS AND THEIR USE IN MODIFYING PRENYLFLAVONOID PRODUCTION IN PLANTS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2009-09-03 US claimed
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECH INC (US) 2026-04-09 US disclosed
US-20260033492-A1 Pest Repellents and Uses Thereof SENSORYGEN INC (US) 2026-02-05 US disclosed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20250204541-A1 GAS PHASE TREATMENT OF PRODUCE APEEL TECHNOLOGY, INC. 2025-06-26 US disclosed
US-6093411-A AN EMULSION COMPRISING FLAVONOIDS FOR PREVENTING OR TREATING SKIN DISORDERS THE PROCTER & GAMBLE COMPANY (US) 2000-07-25 US disclosed
US-6051602-A METHODS FOR PREVENTION OR TREATING SKIN DISORDERS USING FLAVONOID COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2000-04-18 US disclosed
WO-1999047118-A1 COMPOSITIONS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed
WO-1999047113-A1 COMPOSITIONS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed
WO-1999047119-A1 METHODS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 MAPT 1236/4885KMT2A 2456/4885MAOA 3649/4885
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 MAPT 1236/4885KMT2A 2456/4885MAOA 3649/4885
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA NOTCH1, DNER, NOTCH2 MAPT 4067/4885KMT2A 910/4885MAOA 4765/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885KMT2A 2792/4885MAOA 1902/4885
US-20260033492-A1 Pest Repellents and Uses Thereof F3, TFPI, FLI1 MAPT 122/4885KMT2A 1811/4885MAOA 602/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885MAOA 3145/4885
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES CYP51A1, ERG28, NISCH MAPT 4702/4885KMT2A 1152/4885MAOA 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.